Loading...

Agenus

DB:AJ81
Snowflake Description

Limited growth with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AJ81
DB
$340M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
  • Agenus has significant price volatility in the past 3 months.
AJ81 Share Price and Events
7 Day Returns
-6.1%
DB:AJ81
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-26.2%
DB:AJ81
-10.2%
DE Biotechs
-6%
DE Market
AJ81 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Agenus (AJ81) -6.1% -12.8% -33.8% -26.2% -38.6% 13.7%
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • AJ81 underperformed the Biotechs industry which returned -10.2% over the past year.
  • AJ81 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
AJ81
Industry
5yr Volatility vs Market
Related Companies

AJ81 Value

 Is Agenus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Agenus to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Agenus.

DB:AJ81 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AJ81
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (4.07%))
1.331
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.33
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.331 * 5.96%)
8.16%

Discounted Cash Flow Calculation for DB:AJ81 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Agenus is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:AJ81 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.16%)
2019 -123.10 Analyst x1 -113.81
2020 -159.80 Analyst x1 -136.59
2021 -157.00 Analyst x1 -124.07
2022 -85.90 Analyst x1 -62.76
2023 21.50 Analyst x1 14.52
2024 30.25 Est @ 40.69% 18.89
2025 38.88 Est @ 28.55% 22.45
2026 46.68 Est @ 20.05% 24.92
2027 53.27 Est @ 14.11% 26.29
2028 58.56 Est @ 9.94% 26.72
Present value of next 10 years cash flows $-303.44
DB:AJ81 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $58.56 × (1 + 0.23%) ÷ (8.16% – 0.23%)
$739.84
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $739.84 ÷ (1 + 8.16%)10
$337.60
DB:AJ81 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-303.44 + $337.60
$34.16
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $34.16 / 134.21
$0.25
DB:AJ81 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AJ81 represents 0.87194x of NasdaqCM:AGEN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87194x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 0.25 x 0.87194
€0.22
Value per share (EUR) From above. €0.22
Current discount Discount to share price of €2.21
= -1 x (€2.21 - €0.22) / €0.22
-894%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Agenus is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Agenus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Agenus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AJ81 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.44
NasdaqCM:AGEN Share Price ** NasdaqCM (2019-04-18) in USD $2.53
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Agenus.

DB:AJ81 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AGEN Share Price ÷ EPS (both in USD)

= 2.53 ÷ -1.44

-1.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Agenus is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Agenus is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Agenus's expected growth come at a high price?
Raw Data
DB:AJ81 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
7.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Agenus, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Agenus's assets?
Raw Data
DB:AJ81 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-1.44
NasdaqCM:AGEN Share Price * NasdaqCM (2019-04-18) in USD $2.53
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:AJ81 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AGEN Share Price ÷ Book Value per Share (both in USD)

= 2.53 ÷ -1.44

-1.76x

* Primary Listing of Agenus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Agenus has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Agenus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Agenus has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AJ81 Future Performance

 How is Agenus expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
7.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Agenus expected to grow at an attractive rate?
  • Unable to compare Agenus's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Agenus's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Agenus's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:AJ81 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AJ81 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 7.1%
DB:AJ81 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 43%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AJ81 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AJ81 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 175 -89 2
2022-12-31 101 -147 2
2021-12-31 25 -189 2
2020-12-31 9 -188 2
2019-12-31 25 -157 2
DB:AJ81 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 37 -131 -160
2018-09-30 39 -121 -147
2018-06-30 29 -123 -151
2018-03-31 18 -120 -158
2017-12-31 43 -94 -121
2017-09-30 40 -84 -112
2017-06-30 41 -82 -116
2017-03-31 44 -73 -113
2016-12-31 23 -80 -127
2016-09-30 25 -83 -117
2016-06-30 27 -78 -89
2016-03-31 27 -72 -101

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Agenus is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Agenus's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AJ81 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Agenus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AJ81 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.69 -0.12 -1.26 2.00
2022-12-31 -1.15 -0.93 -1.36 2.00
2021-12-31 -1.48 -1.45 -1.51 2.00
2020-12-31 -1.48 -1.40 -1.56 2.00
2019-12-31 -1.27 -1.11 -1.43 2.00
DB:AJ81 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.44
2018-09-30 -1.39
2018-06-30 -1.48
2018-03-31 -1.57
2017-12-31 -1.23
2017-09-30 -1.18
2017-06-30 -1.26
2017-03-31 -1.27
2016-12-31 -1.46
2016-09-30 -1.35
2016-06-30 -1.04
2016-03-31 -1.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Agenus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Agenus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Agenus has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AJ81 Past Performance

  How has Agenus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Agenus's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Agenus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Agenus's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Agenus's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Agenus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Agenus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AJ81 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 36.78 -159.90 37.34
2018-09-30 38.69 -147.18 37.40
2018-06-30 29.24 -150.89 36.25
2018-03-31 17.56 -157.94 34.90
2017-12-31 42.88 -120.90 33.74
2017-09-30 40.10 -111.99 32.63
2017-06-30 41.19 -115.92 32.68
2017-03-31 43.57 -112.52 31.66
2016-12-31 22.57 -127.20 33.13
2016-09-30 24.64 -116.68 32.92
2016-06-30 27.04 -89.03 31.22
2016-03-31 26.82 -101.12 32.11
2015-12-31 24.82 -88.08 28.37
2015-09-30 18.80 -98.46 24.95
2015-06-30 13.51 -93.44 23.46
2015-03-31 10.21 -61.07 21.57
2014-12-31 6.98 -42.69 21.25
2014-09-30 5.75 -22.49 19.58
2014-06-30 4.92 -21.70 18.24
2014-03-31 2.66 -24.80 16.76
2013-12-31 3.05 -33.23 14.48
2013-09-30 3.74 -33.04 13.76
2013-06-30 3.88 -31.60 12.77
2013-03-31 3.70 -27.53 11.48
2012-12-31 15.96 -12.12 11.47
2012-09-30 15.51 -12.70 11.53
2012-06-30 15.30 -12.50 11.51 -5.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Agenus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Agenus has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Agenus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Agenus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Agenus has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AJ81 Health

 How is Agenus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Agenus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Agenus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Agenus's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Agenus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Agenus has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Agenus Company Filings, last reported 3 months ago.

DB:AJ81 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -134.67 13.83 53.05
2018-09-30 -131.39 13.74 46.17
2018-06-30 -113.09 13.74 43.16
2018-03-31 -113.23 13.47 52.35
2017-12-31 -75.82 163.02 60.19
2017-09-30 -51.59 143.94 70.05
2017-06-30 -17.48 139.14 96.77
2017-03-31 8.90 134.83 123.82
2016-12-31 -39.13 130.69 76.44
2016-09-30 -21.04 126.41 95.40
2016-06-30 16.88 122.27 123.29
2016-03-31 44.45 118.31 148.23
2015-12-31 70.73 114.47 171.67
2015-09-30 76.98 110.70 199.13
2015-06-30 87.19 11.43 139.64
2015-03-31 46.26 11.50 79.30
2014-12-31 23.02 6.03 40.22
2014-09-30 48.87 6.72 52.91
2014-06-30 57.63 7.43 62.82
2014-03-31 63.29 9.36 73.49
2013-12-31 -4.48 8.87 27.35
2013-09-30 -2.88 9.33 30.20
2013-06-30 -17.26 9.23 13.44
2013-03-31 -22.68 36.35 17.21
2012-12-31 -17.60 35.92 21.47
2012-09-30 -13.16 35.51 24.76
2012-06-30 -11.36 35.20 25.46
  • Agenus has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Agenus's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Agenus has less than a year of cash runway based on current free cash flow.
  • Agenus has less than a year of cash runway if free cash flow continues to grow at historical rates of 23.1% each year.
X
Financial health checks
We assess Agenus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Agenus has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AJ81 Dividends

 What is Agenus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Agenus dividends.
If you bought €2,000 of Agenus shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Agenus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Agenus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AJ81 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AJ81 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Agenus has not reported any payouts.
  • Unable to verify if Agenus's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Agenus's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Agenus has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Agenus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Agenus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Agenus has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AJ81 Management

 What is the CEO of Agenus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Garo Armen
COMPENSATION $3,769,681
AGE 65
TENURE AS CEO 25.3 years
CEO Bio

Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agenus Inc. since 1999. He served as the President of Antigenics since January 2002. Prior to Agenus Inc., he established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Since 1990, Dr. Armen served as the Managing General Partner of Armen Partners, LP, an investment partnership specializing in public and private healthcare and biotechnology investments. He previously served as Senior Vice President of Research for Dean Witter Reynolds, Research Division, focusing on the chemical and pharmaceutical industries and with E.F. Hutton & Company as first Vice President of research. He serves as the Chairman of Protagenic Therapeutics Inc. and Elan Drug Delivery Inc. Dr. Armen served as Chairman of Elan Corporation, plc from July 2002 to January 2005. He has been a Director of Philips Solid-State Lighting Solutions, Inc. (formerly, Color Kinetics Inc.) since 1998. He serves as a Director of ScrollMotion, Inc. He served as a Non Executive Director of Elan Corporation, plc from February 1994 to May 2006. He has served as an Associate Professor at the Merchant Marine Academy and as a Research Associate at the Brookhaven National Laboratory. In 2002, he founded the Children of Armenia Fund and serves as its Chairman. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. He was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received his Ph.D. in Physical Organic Chemistry from the City University of New York in 1979.

CEO Compensation
  • Garo's compensation has increased whilst company is loss making.
  • Garo's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Agenus management team in years:

1.5
Average Tenure
59
Average Age
  • The average tenure for the Agenus management team is less than 2 years, this suggests a new team.
Management Team

Garo Armen

TITLE
Founder
COMPENSATION
$4M
AGE
65
TENURE
25.3 yrs

Christine Klaskin

TITLE
Principal Accounting Officer & VP of Finance
COMPENSATION
$497K
AGE
52
TENURE
12.5 yrs

Alex Duncan

TITLE
CTO & Head of Research
COMPENSATION
$858K
AGE
56
TENURE
3.3 yrs

Bob Stein

TITLE
Senior R&D Advisor
COMPENSATION
$1M
AGE
67
TENURE
2 yrs

Chris Cortis

TITLE
Chief Strategy Officer & Head of Finance
AGE
50
TENURE
0.8 yrs

Jennifer Buell

TITLE
Chief Operating Officer
TENURE
0.4 yrs

Evan Kearns

TITLE
VP, General Counsel & Secretary
TENURE
0.8 yrs

Ozer Baysal

TITLE
Chief Commercial Officer & Head of HR
COMPENSATION
$462K
AGE
62
TENURE
1.8 yrs

John Castle

TITLE
Head of Translational Medicine & Bioinformatics
TENURE
1.3 yrs

Paulo Moreira

TITLE
Global Head of Clinical Operations
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Agenus board of directors in years:

10.3
Average Tenure
60
Average Age
  • The average tenure for the Agenus board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Garo Armen

TITLE
Founder
COMPENSATION
$4M
AGE
65

Wadih Jordan

TITLE
Independent Director
COMPENSATION
$212K
AGE
83
TENURE
16.1 yrs

Brian Corvese

TITLE
Independent Director
COMPENSATION
$317K
AGE
60
TENURE
12.1 yrs

Tim Wright

TITLE
Lead Director
COMPENSATION
$306K
AGE
60
TENURE
10.3 yrs

Ulf Wiinberg

TITLE
Director
COMPENSATION
$242K
AGE
60
TENURE
2.9 yrs

Allison Jeynes-Ellis

TITLE
Director
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Agenus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Agenus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AJ81 News

Simply Wall St News

AJ81 Company Info

Description

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Details
Name: Agenus Inc.
AJ81
Exchange: DB
Founded: 1994
$301,918,609
134,205,374
Website: http://agenusbio.com
Address: Agenus Inc.
3 Forbes Road,
Lexington,
Massachusetts, 02421,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AGEN Common Stock Nasdaq Capital Market US USD 04. Feb 2000
DB AJ81 Common Stock Deutsche Boerse AG DE EUR 04. Feb 2000
Number of employees
Current staff
Staff numbers
294
Agenus employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 20:38
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/22
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.